<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301284</url>
  </required_header>
  <id_info>
    <org_study_id>CAD1883-211</org_study_id>
    <nct_id>NCT04301284</nct_id>
  </id_info>
  <brief_title>Study of CAD-1883 for Spinocerebellar Ataxia</brief_title>
  <acronym>Synchrony-1</acronym>
  <official_title>Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of CAD-1883 in Adults With Spinocerebellar Ataxia (Synchrony-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cadent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cadent Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral
      administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of
      Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety,
      tolerability, and efficacy of CAD-1883 in the SCA patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral
      administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of SCA using
      multiple dose levels. The study will include multiple cohorts of 16 patients each where 12
      patients will be randomized to CAD-1883 and 4 to matching placebo.

      Potential subjects will undergo a screening period (14 to 28 days), a baseline (Day 1) visit,
      and a 12-week treatment period. A follow-up visit will occur 4 weeks after the end of the
      treatment period. The total duration of individual subject participation may be up to 20
      weeks, depending on the duration of the screening period.

      The study will assess safety by adverse events, vital signs, laboratory parameters (including
      chemistry, hematology and urinalysis); pharmacokinetics of CAD-1883; and efficacy measures by
      Scale for the Assessment and Rating of Ataxia (SARA), clinician/patient rating of ataxia and
      symptoms, patient quality of life measures and wearable sensors to capture falls and gait
      measurements.

      For planning purposes, the anticipated study completion date assumes evaluation of 3 cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Suspended due to COVID-19
  </why_stopped>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of oral administration of CAD-1883 versus placebo: Incidence of Adverse Events</measure>
    <time_frame>12 week treatment period</time_frame>
    <description>Incidence of Adverse Events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Spinocerebellar Ataxias</condition>
  <condition>Spinocerebellar Ataxia Type 1</condition>
  <condition>Spinocerebellar Ataxia Type 2</condition>
  <condition>Spinocerebellar Ataxia Type 3</condition>
  <condition>Spinocerebellar Ataxia Type 6</condition>
  <condition>Spinocerebellar Ataxia Type 7</condition>
  <condition>Spinocerebellar Ataxia Type 8</condition>
  <condition>Spinocerebellar Ataxia Type 10</condition>
  <condition>Spinocerebellar Ataxia Type 17</condition>
  <condition>ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1</condition>
  <arm_group>
    <arm_group_label>CAD-1883</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules of 150 mg of CAD-1883 will be administered orally, twice daily (BID). The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.
The initial dose regimen evaluated will be 150 mg BID. Additional dose regimens up to 600 mg BID will be determined based on forthcoming clinical data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be provided in capsules, to be administered orally, twice daily. The second daily dose will be taken 8 hours (+/- 2 hours) after the first daily dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAD-1883</intervention_name>
    <description>150 mg filled capsules</description>
    <arm_group_label>CAD-1883</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Prior Spinocerebellar Ataxia (SCA) diagnosis of the following SCA genotypes: SCA1, 2,
             3, 6, 7, 8, 10, 17, or Autosomal Recessive Cerebellar Ataxia Type 1 (ARCA1).

          -  Scale for the Assessment and Rating of Ataxia (SARA) Total score ≥8 and &lt;30 at
             Screening

          -  SARA item #1 (gait) score of ≥2 at Screening

          -  Ability to ambulate 8 meters at Screening without assistance from another person

        Key Exclusion Criteria:

          -  Neurological condition other than SCA that could predominantly explain or contribute
             significantly to the subjects' symptoms of ataxia or that could confound the
             assessment of ataxia symptoms (e.g., chronic alcoholism, vitamin deficiencies,
             multiple sclerosis, Parkinson's disease, Friedreich's ataxia, vascular disease,
             tumors, paraneoplastic disease, head injury, idiopathic late onset ataxia, multisystem
             atrophy, stroke, arthritis, cerebral palsy, spasticity of unknown origin).

          -  Moderate or severe scores on the following Inventory of Non-Ataxia Signs (INAS) items
             at Screening: Dystonia: at least 3 of 5 items; Spasticity: at least 2 of 3 items;
             Rigidity: at least 2 of 3 items
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida: Ataxia Research Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ataxia</keyword>
  <keyword>SCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Spinocerebellar Ataxias</mesh_term>
    <mesh_term>Spinocerebellar Degenerations</mesh_term>
    <mesh_term>Machado-Joseph Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

